Premium
The use of mitoxantrone plus cyclophosphamide as first‐line treatment of metastatic breast cancer
Author(s) -
Bezwoda Werner R.,
Hesdorffer Charles
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861015)58:8<1621::aid-cncr2820580806>3.0.co;2-q
Subject(s) - mitoxantrone , medicine , metastatic breast cancer , cyclophosphamide , oncology , breast cancer , chemotherapy , cancer
Thirty‐two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m 2 plus Cyclophosphamide 600 mg/m 2 given at three weekly intervals. Thirty‐one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + Cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.